Trials / Conditions / Stage IV Prostate Adenocarcinoma AJCC v7

Stage IV Prostate Adenocarcinoma AJCC v7

14 registered clinical trials studyying Stage IV Prostate Adenocarcinoma AJCC v7.

Status	Trial	Sponsor	Phase
Completed	Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer NCT03503344	University of California, San Francisco	Phase 2
Terminated	Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Pros NCT03442556	University of Washington	Phase 2
Active Not Recruiting	Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE NCT03371719	NRG Oncology	Phase 2
Completed	Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate C NCT03406858	Barbara Ann Karmanos Cancer Institute	Phase 2
Active Not Recruiting	Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients W NCT03419234	ECOG-ACRIN Cancer Research Group	Phase 2
Active Not Recruiting	Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Canc NCT03456843	Yale University	Phase 2
Completed	ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer NCT03456804	Barbara Ann Karmanos Cancer Institute	Phase 2
Active Not Recruiting	Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With NCT02893917	National Cancer Institute (NCI)	Phase 2
Completed	A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Me NCT02849990	University of Washington	Phase 2
Active Not Recruiting	Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in NCT02703623	M.D. Anderson Cancer Center	Phase 2
Terminated	Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-R NCT02215161	University of California, San Francisco	Phase 2
Completed	Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide NCT02099864	OHSU Knight Cancer Institute	Phase 2
Completed	Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Pr NCT01409200	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer NCT00544830	City of Hope Medical Center	Phase 2